6-(4-aminophenoxy)-hexanoic acid methyl ester | 125173-82-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6-(4-aminophenoxy)-hexanoic acid methyl ester
• 英文别名: methyl 6-(4-aminophenoxy)hexanoate
• CAS: 125173-82-2
• 化学式: C₁₃H₁₉NO₃
• 分子量: 237.299
• InChiKey: XDJLGMFYGWUTAI-UHFFFAOYSA-N

物化性质

• 沸点：
  371.3±22.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4-aminophenoxy)-hexanoic acid methyl ester 在 盐酸 、 溶剂黄146 、 三氯氧磷 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 49.67h， 生成 6-<4-phenoxy>hexanoic acid
  参考文献：
  名称：

  DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard

  摘要：

  A series of DNA-targeted aniline mustards have been prepared, and their chemical reactivity and in vitro and in vivo cytotoxicity have been evaluated and compared with that of the corresponding simple aniline mustards. The alkylating groups were anchored to the DNA-intercalating 9-aminoacridine chromophore by an alkyl chain of fixed length attached at the mustard 4-position through a link group X, while the corresponding simple mustards possessed an electronically identical small group at this position. The link group was varied to provide a series of compounds of similar geometry but widely differing mustard reactivity. Variation in biological activity should then largely be a consequence of this varying reactivity. Rates of mustard hydrolysis in the two series related only to the electronic properties of the link group, with attachment of the intercalating chromophore having no effect. The cytotoxicities of the simple mustards correlated well with group electronic properties (with a 200-300-fold range in IC50S). The corresponding DNA-targeted mustards were much more potent (up to 100-fold), but their IC50 values varied much less with linker group electronic properties. Most of the DNA-targeted mustards showed in vivo antitumor activity, being both more active and more dose-potent than either the corresponding untargeted mustards and chlorambucil. These results show that targeting alkylating agents to DNA by attachment to DNA-affinic units may be a useful strategy.

  DOI：

  10.1021/jm00166a015
• 作为产物：
  描述：

  6-(4-硝基苯氧基)己酸甲酯 在 镍 氢气 、 N,N-二甲基甲酰胺 、 silica gel 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to get pure 17 (28 grams, 78.8%) as a thick brown syrup的产率得到6-(4-aminophenoxy)-hexanoic acid methyl ester
  参考文献：
  名称：

  Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices

  摘要：

  由至少选择自以下化合物之一或其相应的二胺或二异氰酸酯制备的可吸收聚氨酯、聚酰胺和聚酯-聚氨酯制备而成，其中每个X独立地表示-CH2COO-，-CH（CH3）COO-，-CH2CH2OCH2COO-，-CH2CH2CH2CH2CH2COO-，-（CH2）yCOO-，其中y为2至4或6至24，或-（CH2CH2O）z'CH2COO-，其中z'为2至24；每个Y表示-COCH2O-，-COCH（CH3）O-，-COCH2OCH2CH2O-，-COCH2CH2CH2CH2CH2O-，-CO（CH2）mO-，其中m为2至4或6至24，或-COCH2O（CH2CH2O）n-，其中n为2至24；R'为氢，苄基或直链或支链烷基；p为1至4；并且Rn表示选择自H，烷氧基，苄氧基，醛基，卤素，羧酸和-NO2的一个或多个成员，其直接连接到芳香环或通过脂肪链连接。从这些化合物制备的可吸收聚合物对于药物传递、组织工程、组织粘合剂、粘附防止和其他可植入医疗设备非常有用。

  公开号：

  US08846845B2

文献信息

• Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
  作者：Shipeng He、Guoqiang Dong、Yu Li、Shanchao Wu、Wei Wang、Chunquan Sheng

  DOI：10.1002/ange.201915896

  日期：2020.2.17

  of more effective therapy for the treatment of pancreatic cancer. Reported here is a new, effective therapeutic strategy and the design of small‐molecule inhibitors that simultaneously target bromodomain and extra‐terminal (BET) and histone deacetylase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer. A highly potent dual inhibitor (13 a) is identified to possess excellent

  摘要作为人类最具侵袭性和致死性的恶性肿瘤之一，预后极差，迫切需要更有效的治疗方法来治疗胰腺癌。这里报道了一种新的、有效的治疗策略和小分子抑制剂的设计，同时靶向溴结构域和额外末端（BET）和组蛋白脱乙酰酶（HDAC），有可能成为胰腺癌的有前途的治疗药物。一种高效的双重抑制剂（13 一个）被确定具有针对 BRD4 BD1（IC50=11n米）和 HDAC1（IC50=21n米）。值得注意的是，该化合物在体外和体内均表现出比 BET 抑制剂 (+)-JQ1 和 HDAC 抑制剂伏立诺他单独或联合使用更高的抗肿瘤效力，凸显了 BET/HDAC 双重抑制剂在更有效治疗胰腺癌方面的优势。癌症。
• Functionalized drugs and polymers derived therefrom
  申请人：Bezwada S. Rao

  公开号：US20060172983A1

  公开（公告）日：2006-08-03

  Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

  从中选择的化合物：其中DRUG-OH，DRUG-COOH和DRUG-NH2是生物活性化合物；每个X独立地从— COO—（乙二酸基团），—CH(CH3)COO—（乳酸基团），— O COO—（二氧杂环己酮基团），— COO—（己内酯基团），—(CH2)yCOO—中选择，其中y为2-4或6-24和—( O)z COO—，其中z为2-24；每个Y独立地从—CO O—（乙二酸酯基团），—COCH( )O—（乳酸酯基团），—CO O O—（二氧杂环己酮酯基团），—CO O—（己内酯酯基团），—CO( )mO—，其中m为2-4或6-24和—CO O( O)n—，其中n为2-24；R′为氢，苄基或烷基，烷基可以是直链或支链；p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
• FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM
  申请人：Bezwada Rao S.

  公开号：US20090170927A1

  公开（公告）日：2009-07-02

  The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same. Ar—[O—(X) p —R′] q I Polymers formed from the functionalized phenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.

  本发明涉及公式I的化合物，这些化合物是官能化酚类化合物，以及由它们形成的聚合物。从官能化酚类化合物形成的聚合物预计具有可控的降解特性，使它们能够在所需的时间范围内释放活性成分。这些聚合物还预计在各种医疗应用中有用。
• Functionalized phenolic esters and amides and polymers therefrom
  申请人：Bezwada S. Rao

  公开号：US20060173065A1

  公开（公告）日：2006-08-03

  The present invention relates to a compound of the formula: R-AR—O—Y—R′ Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO 2 , —NH 2 , —NHCOCH 3 , and —NH—Y—R′, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicylic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group. Y represents a member selected from: —COCH 2 O— (glycolic ester moiety) —COCH(CH 3 )O— (lactic ester moiety) —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety) —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety) —CO(CH 2 ) m O— where m is an integer between 2-4 and 6-24 inclusive —COCH 2 O(CH 2 CH 2 O) n — where n is an integer between 2 and 24, inclusive; and R′ is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched. The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.

  本发明涉及一种化合物，其化学式为：R-AR—O—Y—R′，其中R代表从H、烷氧基、苯甲氧基、醛基、卤素、羧酸、—NO2、—NH2、—NHCO 和—NH—Y—R′中选择的一个或多个成员，该成员直接附着在AR上或通过脂肪链连接。R中的羧酸基团包括但不限于以下羧酸：苯甲酸、肉桂酸、阿魏酸、咖啡酸、槲皮酸、水杨酸、香草酸、苯乙酸、苯丙酸和芥子酸。-AR—O—是一个生物活性的酚基团，包括1到6个取代或未取代的芳香环直接连接、融合或通过连接基团连接的环。Y代表从以下成员中选择：—CO O—（乙二醇酯基团）—COCH(CH3)O—（乳酸酯基团）—CO O O—（二氧环酮酯基团）—CO O—（己内酯酯基团）—CO(CH2)mO—其中m是2-4和6-24之间的整数—CO O( O)n—其中n是2到24之间的整数；R′是氢或苄基或烷基，烷基可以是直链或支链。所得的功能化酚类化合物单独或组合使用，其聚合物具有可控的降解特性，释放所需时间范围内的活性成分。该聚合物对于生物材料和生物医学器械有用，其中所述的生物活性酚基团是酚类化合物的残留物。
• BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES
  申请人：Bezwada Rao S.

  公开号：US20120158127A1

  公开（公告）日：2012-06-21

  Absorbable polyurethanes, polyamides and polyester urethanes prepared from at least one compound selected from: or the corresponding diamines or diisocyanates thereof, wherein each X independently represents —CH 2 COO—, —CH(CH 3 )COO—, —CH 2 CH 2 OCH 2 COO—, —CH 2 CH 2 CH 2 CH 2 CH 2 COO—, —(CH 2 ) y COO— where y is 2 to 4 or 6 to 24, or —(CH 2 CH 2 O) z′ CH 2 COO— where z′ is 2 to 24; each Y represents —COCH 2 O—, —COCH(CH 3 )O—, —COCH 2 OCH 2 CH 2 O—, —COCH 2 CH 2 CH 2 CH 2 CH 2 O—, —CO(CH 2 ) m O— where m is 2 to 4 or 6 to 24, or —COCH 2 O(CH 2 CH 2 O) n — where n is 2 to 24; R′ is hydrogen, benzyl or straight-chained or branched alkyl; p is 1 to 4; and Rn represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid and —NO 2 , which is attached directly to an aromatic ring or attached through an aliphatic chain. Absorbable polymers prepared from these compounds are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention and other implantable medical devices.

  可吸收的聚氨酯、聚酰胺和聚酯尿素是由至少一种选择自以下化合物或其相应的二胺或二异氰酸酯制备而成：其中每个X独立地表示- COO-、-CH(CH3)COO-、- O COO-、- COO-、-(CH2)yCOO-，其中y为2至4或6至24，或-( O)z' COO-，其中z'为2至24；每个Y表示-CO O-、-COCH( )O-、-CO O O-、-CO O-、-CO( )mO-，其中m为2至4或6至24，或-CO O( O)n-，其中n为2至24；R'为氢、苄基或直链或支链烷基；p为1至4；Rn表示选择自H、烷氧基、苄氧基、醛、卤素、羧酸和-NO2的一个或多个成员，它直接附着在芳香环上或通过脂肪链附着。从这些化合物制备的可吸收聚合物可用于药物输送、组织工程、组织粘合剂、粘着预防和其他可植入医疗器械。